Back to Journals » Clinical Ophthalmology » Volume 5

A rare case of zolendronate infusion complication leading to glaucoma filtration surgery

Authors Khan A, Lascaratos G, Rane-Malcolm, Sanders R

Published 18 August 2011 Volume 2011:5 Pages 1147—1149

DOI https://doi.org/10.2147/OPTH.S22429

Review by Single-blind

Peer reviewer comments 3


A Khan1, G Lascaratos1, T Rane-Malcolm2, R Sanders2
1Princess Alexandra Eye Pavilion, Edinburgh, 2Department of Ophthalmology, Queen Margaret Hospital, Dunfermline, Fife, UK

Abstract: Zolendronic acid is a nitrogenous biphosphonate commonly used as an intravenous infusion for the management of Paget’s disease, osteoporosis, and hypercalcemia of malignancy. We report a rare and challenging complication of zolendronate infusion: unilateral acute anterior uveitis followed by persistently raised intraocular pressure despite being on four different classes of antiglaucoma medication. The challenge was that the patient required topical steroid to treat her uveitis in the background of known glaucoma with corresponding steroid response. She eventually underwent a left phacotrabeculectomy augmented with 5-fluorouracil. Four weeks postoperatively she developed an encapsulated bleb and underwent needling with 5-fluorouracil. This case highlights the importance of having a high index of suspicion for anterior uveitis in patients with a red and painful eye after initiating biphosphonate therapy. Caution should also be exercised when prescribing biphosponates to glaucoma patients.

Keywords: biphosponates, anterior uveitis, intraocular pressure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]